Comparison of fluconazole and nystatin oral suspensions for prophylaxis of systemic fungal infection in very low birthweight infants

American Journal of Perinatology

Volumn 27, Issue 1, 2010, Pages 73-78

  Violaris, Kimon ^a   Carbone, Tracy ^b   Bateman, David ^a   Olawepo, Olajide ^c   Doraiswamy, Brinda ^d   Lacorte, Meena ^e  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b VALLEY HOSPITAL   (United States)

^c Peninsula Hospital Center   (United States)

^d NASSAU UNIVERSITY MEDICAL CENTER   (United States)

^e INTERFAITH MEDICAL CENTER   (United States)

Author keywords

Fluconazole; Fungal infections; Nystatin; Very low birthweight infants

Indexed keywords

FLUCONAZOLE; NYSTATIN;

ARTICLE; BLOOD CULTURE; CANDIDA ALBICANS; CANDIDA KRUSEI; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; FEEDING; FEMALE; FUNGAL COLONIZATION; GESTATIONAL AGE; HOSPITALIZATION; HUMAN; INFANT; INFECTION PREVENTION; INTESTINE PERFORATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; NECROTIZING ENTEROCOLITIS; NEWBORN SEPSIS; PREMATURITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; STAPHYLOCOCCAL BACTEREMIA; SYSTEMIC MYCOSIS; TREATMENT DURATION; URINE CULTURE; VERY LOW BIRTH WEIGHT;

ADMINISTRATION, ORAL; ANTIFUNGAL AGENTS; FLUCONAZOLE; HUMANS; INFANT, NEWBORN; INFANT, VERY LOW BIRTH WEIGHT; MYCOSES; NYSTATIN; TREATMENT OUTCOME;

EID: 74549125473     PISSN: 07351631     EISSN: 10988785     Source Type: Journal    
DOI: 10.1055/s-0029-1224871     Document Type: Article

References (30)

1. Stoll B J., Hansen N, Fanaroff A A. et al. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics 2002 110 (2 Pt 1) 285-291
2. Makhoul I R., Sujov P, Smolkin T, Lusky A, Reichman B. Epidemiological, clinical, and microbiological characteristics of late-onset sepsis among very low birth weight infants in Israel: a national survey. Pediatrics 2002 109 (1) 34-39
3. Kossoff E H., Buescher E S., Karlowicz M G. Candidemia in a neonatal intensive care unit: trends during fifteen years and clinical features of 111 cases. Pediatr Infect Dis J 1998 17 (6) 504-508
4. Fanaroff A A., Korones S B., Wright L L. et al, The National Institute of Child Health and Human Development Neonatal Research Network. Incidence, presenting features, risk factors and significance of late onset septicemia in very low birth weight infants. Pediatr Infect Dis J 1998 17 (7) 593-598
5. Benjamin D K. Jr, Stoll B J., Fanaroff A A. et al, National Institute of Child Health and Human Development Neonatal Research Network. Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months. Pediatrics 2006 117 (1) 84-92
6. Saiman L, Ludington E, Pfaller M et al. Risk factors for candidemia in Neonatal Intensive Care Unit patients. The National Epidemiology of Mycosis Survey study group. Pediatr Infect Dis J 2000 19 (4) 319-324
7. Mittal M, Dhanireddy R, Higgins R D. Candida sepsis and association with retinopathy of prematurity. Pediatrics 1998 101 (4 Pt 1) 654-657
8. Friedman S, Richardson S E., Jacobs S E., O'Brien K. Systemic Candida infection in extremely low birth weight infants: short term morbidity and long term neurodevelopmental outcome. Pediatr Infect Dis J 2000 19 (6) 499-504
9. Faix R G., Kovarik S M., Shaw T R., Johnson R V. Mucocutaneous and invasive candidiasis among very low birth weight (less than 1,500 grams) infants in intensive care nurseries: a prospective study. Pediatrics 1989 83 (1) 101-107
10. Rowen J L., Rench M A., Kozinetz C A., Adams J M. Jr, Baker C J. Endotracheal colonization with Candida enhances risk of systemic candidiasis in very low birth weight neonates. J Pediatr 1994 124 (5 Pt 1) 789-794
11. Austin N C., Darlow B. Prophylactic oral antifungal agents to prevent systemic candida infection in preterm infants. Cochrane Database Syst Rev 2004 (1) CD003478
12. McGuire W, Clerihew L, Austin N. Prophylactic intravenous antifungal agents to prevent mortality and morbidity in very low birth weight infants. Cochrane Database Syst Rev 2004 (1) CD003850
13. Sims M E., Yoo Y, You H, Salminen C, Walther F J. Prophylactic oral nystatin and fungal infections in very-low-birthweight infants. Am J Perinatol 1988 5 (1) 33-36
14. Ozturk M A., Gunes T, Koklu E, Cetin N, Koc N. Oral nystatin prophylaxis to prevent invasive candidiasis in neonatal intensive care unit. Mycoses 2006 49 484-492
15. Kaufman D, Boyle R, Hazen K C., Patrie J T., Robinson M, Donowitz L G. Fluconazole prophylaxis against fungal colonization and infection in preterm infants. N Engl J Med 2001 345 (23) 1660-1666
16. Kicklighter S D., Springer S C., Cox T, Hulsey T C., Turner R B. Fluconazole for prophylaxis against candidal rectal colonization in the very low birth weight infant. Pediatrics 2001 107 (2) 293-298
17. Manzoni P, Arisio R, Mostert M et al. Prophylactic fluconazole is effective in preventing fungal systemic infections in preterm neonates: A single-center, 6-year, retrospective cohort study. Pediatrics 2006 117 e22-e32
18. Uko S, Soghier L M., Vega M et al. Targeted short-term fluconazole prophylaxis among very low birth weight and extremely low birth weight infants. Pediatrics 2006 117 (4) 1243-1252
19. Bertini G, Perugi S, Dani C, Filippi L, Prates S, Rubaltelli F F. Fluconazole prophylaxis prevents invasive fungal invasive infection in high-risk, very low birth weight infants. J Pediatr 2005 147 162-165
20. Healy C M., Baker C J., Zaccaria E, Campbell J R. Impact of fluconazole prophylaxis on incidence and outcome of invasive candidiasis in a neonatal intensive care unit. J Pediatr 2005 147 (2) 166-171
21. Burwell L A., Kaufman D, Blakely J, Stoll B J., Fridkin S K. Antifungal prophylaxis to prevent neonatal candidiasis: a survey of perinatal physician practices. Pediatrics 2006 118 (4) e1019-e1026
22. U.S. Food and Drug Administration. Approval letter, final printed labeling, and chemistry review(s). Nystatin oral suspension USP. Approval date: June 25, 1998. Available at www.fda.gov/cder/foi/anda/98/64142.htm Accessed April 14, 2009
23. Antifungal agents for common paediatric infections. Paediatr Child Health 2007 12 (10) 875-883
24. Mutz A E., Obladen M W. Hyperosmolar oral medication and necrotizing enterocolitis. Pediatrics 1985 75 (2) 371-372
25. Novelli V, Holzel H. Safety and tolerability of fluconazole in children. Antimicrob Agents Chemother 1999 43 (8) 1955-1960
26. Charlier C, Hart E, Lefort A et al. Fluconazole for the management of invasive candidiasis: where do we stand after 15 years? J Antimicrob Chemother 2006 57 (3) 384-410
27. Flynn P M., Cunningham C K., Kerkering T et al, The Multicenter Fluconazole Study Group. Oropharyngeal candidiasis in immunocompromised children: a randomized, multicenter study of orally administered fluconazole suspension versus nystatin. J Pediatr 1995 127 (2) 322-328
28. Groll A H., Just-Nuebling G, Kurz M et al. Fluconazole versus nystatin in the prevention of candida infections in children and adolescents undergoing remission induction or consolidation chemotherapy for cancer. J Antimicrob Chemother 1997 40 (6) 855-862
29. Kaufman D, Fairchild K D. Clinical microbiology of bacterial and fungal sepsis in very-low-birth-weight infants. Clin Microbiol Rev 2004 17 (3) 638-680
30. Aghai Z H., Mudduluru M, Nakhla T A. et al. Fluconazole prophylaxis in extremely low birth weight infants: association with cholestasis. J Perinatol 2006 26 (9) 550-555